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The therapeutic efﬁcacy of allogeneic peripheral blood stem cell transplantation (PBSCT) for hematological
malignancies relies largely on the graft-versus-leukemia (GVL) effects exerted by the donor CD3 cells, but there
is a risk of onset of uncontrolled graft-versus-host disease (GVHD). Regulatory T cells (Tregs) (CD4þCD25high
Foxp3þ) are believed to maintain tolerance and to inhibit acute GVHD (aGVHD) after allogeneic PBSCT.
Nevertheless, when looking at post-allotransplantation patient outcomes, although the impact of aGVHD on
survival is amply documented, so far there is no evidence that the donor graft CD3/Tregs ratiomayaffect overall
survival (OS), nonrelapse mortality (NRM), disease-free survival (DFS), and relapse rates. Our aimwas to study
the possible impact of the gCD3/Tregs ratio on survival after myeloablative allogeneic PBSCT. We analyzed 74
consecutive patients diagnosed with acute myeloid leukemia (n ¼ 62), acute lymphoblastic leukemia (n¼ 10),
and chronic myeloid leukemia (n ¼ 2) who underwent transplantation with unmanipulated PBSCs from
a human leukocyte antigeneidentical related donor (n¼ 48) or a human leukocyte antigeneidentical unrelated
donor (n¼ 26). Patients were subdivided into a high gCD3/Tregs ratio (36) group (HR group, n¼ 30) and a low
gCD3/Tregs ratio (<36) group (LR group, n¼ 44). The OS, DFS, NRM, and relapse rates at 3 years were 53%, 51%,
29%, and 34%, respectively. Comparing the LR and HR groups, a statistically signiﬁcant difference was
demonstrated for the 3-year OS, DFS, and NRM rates (65% vs 31%, P¼ .0001; 67 versus 26%, P¼ .0001; 5% versus
71%, P < .0001, respectively) but not for relapse (30% vs 25%, P ¼ ns). By multivariate analysis, LR signiﬁcantly
predicted better OS (P ¼ .019), DFS (P ¼ .003), and NRM (P ¼ .05), whereas there was no statistically signiﬁcant
association between LR and relapse (P¼ .155). Overall, our datamay suggest that LR preserves GVL effects but is
also protective against aGVHD in allotransplantation patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION models [2]. The pathophysiological link between GVHD and
The contribution of regulatory T cells (Tregs) to post-
transplantation immunological reconstitution has been
clearly established, given their impact on T cell immunity [1]
and on modulating graft-versus-host disease (GVHD) while
preserving graft-versus-leukemia (GVL) effects in mouseimmune reconstitution is well deﬁned [3,4]. Therefore, given
that acute GVHD (aGVHD) is triggered by alloreactive mature
donor CD3 T cells [5,6] and antagonized by Tregs [7,8], the
immunity of patients undergoing allotransplantation might
depend on the ratio between these two cellular populations,
as we have already suggested in humans [9], in line with
murine experimental models of aGVHD [10,11].
Moreover, it is well known that, apart from inducing
prolonged immunosuppression [12] and a graft failure risk
[13], T cell depletion of the donor graft results in a higher
leukemia relapse rate [14]. Nevertheless, when looking at the
outcomes of patients undergoing allotransplantation,
although the impact of human leukocyte antigen (HLA)
incompatibility (and of the consequent aGVHD) on patient
Table 1
Patient Characteristics
n %
Patients 74
Sex (male/female) 34/40 46/
54
Median age, y 33 (18-61)
Diagnosis
Acute myeloid leukemia 62 84
Acute lymphoblastic leukemia 10 13
Chronic myeloid leukemia 2 3
Conditioning regimen
Busulfan þ cyclophosphamide 74 100
Donor
Sibling-matched donor 48 65
Unrelated matched donor 26 35
HCT-CI
0 40 54
1-2 23 31
3 11 15
Graft CD3/Tregs ratio
LR <36 44 60
HR 36 30 40
rATG usage
Yes 26 35
No 48 65
Source of stem cells
PBSC 74 100
GVHD prophylaxis
CsA þ MTX 74 100
HCT-CI indicates hematopoietic cell transplantation-speciﬁc comorbidity
index; rATG, rabbit antithymocyte globulin; CsA, cyclosporin; MTX,
methotrexate.
Table 2
Comparison between Patients with High and Low Graft CD3/Tregs Ratio
HR Group
(n ¼ 30)
LR Group
(n ¼ 44)
Median age, y 37 35 ns
Median graft CD3/Tregs ratio value 83 15 <.001
Grades II-IV aGVHD, n (%) <.001
Yes 26 (87) 8 (18)
No 4 (13) 36 (82)
Sex mismatched, n (%) 17 (57) 25 (57) ns
HCT-CI, n (%) ns
<3 28 (93) 35 (79)
3 3 (7) 8 (21)
HLA MUD disparity, n (%)
10/10 8 (27) 11 (25) ns
9/10 3 (10) 4 (9)
Donor, n (%)
Sibling 19 (63) 29 (66) ns
MUD 11 (37) 15 (34)
rATG usage, n (%) ns
Yes 11 (37) 15 (34)
No 19 (63) 29 (66)
GVHD prophylaxis, n (%) ns
CsA þ MTX 30 (100) 44 (100)
HCT-CI indicates hematopoietic cell transplantation-speciﬁc comorbidity
index; MUD, matched unrelated donor; rATG, rabbit antithymocyte glob-
ulin; CsA, cyclosporin; MTX, methotrexate.
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that donor CD3 T cells, if analyzed together with Tregs
(gCD3/Tregs ratio), may have an impact in terms of post-
transplantation outcomes (ie, overall survival [OS], non-
relapse mortality [NRM], disease-free survival [DFS], and
relapse rates). In this study, we expanded the previous
evaluation [9] of the contribution of the graft CD3/Tregs ratio
on aGVHD and immune recovery to focus on the possible
impact of a low gCD3/Tregs ratio (LR) or high gCD3/Tregs
ratio (HR) on OS, DFS, NRM, and relapse rates.
METHODS
Patients
Seventy-four patients who underwent allogeneic peripheral blood stem
cell (PBSC) transplantation between January 2006 and December 2011 were
included in this retrospective study; written informed consent was obtained
from all patients. Patient characteristics are shown in Table 1.
All patients received PBSC grafts from an HLA-identical sibling donor
(n ¼ 48) or an unrelated HLA-identical donor (n ¼ 26). DNA-based HLA
typing of donor and recipientwas done using high resolution (four digits) for
HLA-A, -B, -C, -DRB1, and -DQB1; in unrelated transplantation, a complete
match (10 of 10) was documented in 19 donorepatient pairs (73%) and
a partial match (9 of 10) in 7 donorepatient mismatched pairs (27%). As
conditioning regimen, all patients underwent a conventional myeloablative
regimen that included 16 mg/kg oral busulfan (12.8 mg/kg intravenously in
the last 9 patients) and 120 mg/kg cyclophosphamide. Antithymocyte
globulin 7.5 mg/kg was administered in unrelated transplantations.
All patients were administered prophylactic antibiotics (levoﬂoxacin
500 mg/d) until neutrophil engraftment; we used ﬂuconazole (400 mg/d to
day 100) as antifungal prophylaxis and trimethoprim-sulfamethoxazole for
Pneumocystis jirovecii prophylaxis. All patients received GVHD prophylaxis,
using cyclosporine A (starting on day 1) and methotrexate (on days 1, 3, 6,
and 11).
Graft Content
The numbers of total nucleated, CD34, CD3, CD4, CD8, natural killer, and
Treg cells in the donor graft were assessed before PBSC infusion. Tregs were
phenotypically analyzed by ﬂow cytometry using a panel of directly
conjugated antibodies to CD3, CD4, CD25 (M-A251), and CD45RO. Fluores-
cein isothiocyanate, Phycoerytherin, peridinin-chlorophyll protein, andallophycocyanin (Beckman Coulter, Miami, FL and BD Biosciences, Franklin
Lakes, NJ) were used as ﬂuorophores. Intracellular analysis of FoxP3 (eBio-
science, San Diego, CA) was performed after ﬁxation and permeabilization
according to the manufacturer’s recommendations. Flow cytometry was
performed with a FACSCalibur ﬂow cytometer (BD Biosciences), and data
were acquired and analyzed using Cellquest software (Becton Dickinson, San
Jose, CA). NK lymphocytes, identiﬁed as CD3 and CD16 and/or CD56 cells,
were analyzed using a multicolor ﬂow cytometric panel with B, T, and NK
cell markers (BD Multitest 6-color TBNK reagent, BD Biosciences). Absolute
counts of viable total nucleated cells and CD34 cells were performed using
FlowCount beads solution on a Cytomics FC500 ﬂow cytometer (Beckman
Coulter) according to the International Society of Hematotherapy and Graft
Engineering protocol.
Evaluation of gCD3/Tregs Ratio, Grades II to IV aGVHD, and Group
Subdivision
The gCD3/Tregs ratio was calculated for all patients at the time of PBSC
infusion. The gCD3/Tregs ratio value associated with the appearance of
aGVHD grade II or greater was36 [9]; therefore, the cohort was subdivided
into two groups: an LR group (<36) and an HR group (36) (Table 2). aGVHD
was diagnosed based on clinical symptoms and/or analysis of biopsy spec-
imens from skin, oral mucosa, liver, and gut and classiﬁed according to the
standard Seattle criteria [17]. All patients with aGVHD grade II or greater
were treated with methylprednisolone at an initial dose of 1 to 2 mg/kg
body weight and then adjusting the dose according to the clinical response.
All patients with aGVHD lower than grade II were classiﬁed as
aGVHDe(Table 2).
Outcomes
OS was deﬁned as the time from transplantation to death for any cause.
DFS was deﬁned as the time from transplantation to relapse or death for any
cause. NRM was deﬁned as death not related to disease recurrence or
progression. Relapse was deﬁned as disease recurrence.
Statistical Analysis
Patient characteristics were compared using the chi-square or Fisher
exact test (as appropriate) in the case of discrete variables and the t-test or
Mann-Whitney test in the case of continuous variables. The endpoints of the
study were the cumulative incidences of relapse and NRM, comparing the
HR and LR groups. Cumulative incidence curves were used in a competing-
risk setting, with relapse and death due to causes independent of relapse
each treated as a competing event to calculate the probability of NRM and
relapse, respectively. The groups were compared with Gray’s k-sample test.
OS was estimated by the Kaplan-Meier method. The OS differences between
groups were calculated by log-rank test. Multivariate analyses of NRM, OS,
DFS, and relapsewere carried out with Cox regression models, treating NRM
and disease relapse as competing events. Critical level of signiﬁcancewas set
at .05.
Figure 1. Study cohort and LR and HR group OS (A), DFS (B), NRM (C), and relapse rates (D). Three-year LR versus HR OS (65% vs 31%; P ¼ .0001), DFS (67% vs 26%;
P ¼ .0001), NRM (3% vs 71%; P < .0001), and relapse (30% vs 25%; P ¼ ns).
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LR Versus HR Group
The differences in terms of HLA disparity, sex mismatch,
donor type, rabbit antithymocyte globulin (rATG) usage,
grade II or greater aGVHD incidence, and hematopoietic cell
transplantation-speciﬁc comorbidity index [18] between the
HR (n ¼ 30 patients) and LR groups (n ¼ 40 patients) are
summarized in Table 2.
When considering rATG usage, we did not ﬁnd any
correlation either with the HR or LR group (11 of 30 [37%] vs
15 of 44 [34%], P ¼ ns; Table 2) or with grades II to IV aGvHD
incidence (11 of 34 [32%] vs 15 of 40 [37%]; P¼ ns). Therewas
no difference in terms of cGVHD incidence between the two
groups (13 of 30 [43%] vs 16 of 44 [36%]; P ¼ ns).Table 3
Cox Multivariate Analysis
OS DFS
P Value Hazard Ratio (95% CI) P Value Hazard Ratio
Ratio (LR vs HR) .019 .319 (.122-.829) .003 .231 (.087-
Disease (AML vs not AML) .519 .769 (
.360-1.675)
.846 .928 (.436-
Pretransplantation status
(1 CR vs not 1 CR)
.563 .791 (.357-1.751) .392 .712 (.327-
Age, y (<55 vs 55) .085 2.489 (.881-7.034) .532 1.404 (.484-
HCT-CI (<3 vs 3) .848 1.129 (.326-3.907) .238 2.147 (.604-
CMV serostatus (high
risk vs not high risk)
.625 1.330 (.424-4.169) .529 1.433 (.468-
HLA mismatched
(yes vs no)
.244 .381 (.0751-1.934) .817 .770 (.084-
Sex mismatched
(RMDF vs other)
.139 .309 (.065-1.466) .089 .163 (.020-
Donor (MUD vs sibling) .734 1.109 (.436-3.244) .865 .915 (.329-
aGVHD grades II-IV
(yes vs no)
.066 .356 (.118-1.072) .722 .829 (.296-
AML indicates acute myeloid leukemia; CR, complete remission; HCT-CI, hematopo
recipient male, donor female; MUD, matched unrelated donor.
Signiﬁcant values are shown in bold.OS, NRM, DFS, and Relapse Rates
Study cohort and LR and HR group univariate OS, DFS,
NRM, and relapse rates are reported in Figure 1. OS, DFS,
NRM, and relapse rates at 3 years for the study cohort were
53%, 51%, 29%, and 34%, respectively. OS, DFS, NRM, and
relapse rates at 3 years for the LR group were 65%, 67%, 5%,
and 30%, respectively, and for the HR group were 31%, 26%,
71%, and 25%, respectively.
Multivariate Analysis of Factors Affecting OS, NRM, DFS,
and Relapse Rates
Variables included in multivariate analysis were gCD3/
Tregs ratio (LR vs HR), type of disease (acute myelogenous
leukemia vs no acute myelogenous leukemia), status atRelapse NRM
(95% CI) P Value Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI)
.603) .155 3.507 (.622-19.783) .05 .300 (.120-1.120)
1.975) .199 .474 (.151-1.481) .750 .808 (.218-2.997)
1.550) .045 .280 (.081-.971) .074 .308 (.085-1.119)
4.073) .604 1.958 (.154-24.906) .006 10.570 (1.950-57.295)
7.638) .270 3.816 (.353-41.201) .169 .239 (.031-1.836)
4.391) .119 .415 (.137-1.254) .198 3.111 (.552-17.533)
7.030) .693 1.907 (.077-47.157) .009 .021 (.001-.382)
1.316) .023 4.358 (1.225-15.502) .246 .330 (.501-2.150)
2.547) <.001 .054 (.014-.213) .690 1.339 (.319-5.626)
2.326) .429 .585 (.155-2.207) .996 .000 (.000-þinf)
ietic cell transplantation comorbidity index; CMV, cytomegalovirus; RMFD,
Table 4
Causes of Death
Cause HR Group LR Group
aGVHD grades II-IV 6 (30) 0
cGVHD 4 (20) 1 (7)
CMV infection 3 (15) 1 (7)
Multiple organ failure/sepsis 2 (10) 4 (29)
Primary disease 5 (25) 5 (36)
Graft failure 0 2 (14)
Toxicity 0 1 (7)
Total 20 14
CMV indicates cytomegalovirus.
Values are number of incidences with percentages in parentheses.
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response), age (<55 and 55 years), cytomegalovirus (CMV)
risk (high vs not high), HLA mismatched, gender mis-
matched, type of donor (sibling vs matched unrelated
donor), and grades II to IV aGVHD. Data are summarized in
Table 3.Causes of NRM
Table 4 shows the causes of death for the LR and HR
groups.DISCUSSION
We already demonstrated a correlation between graft
Tregs and immunological recovery [19] and then between
the gCD3/Tregs ratio and aGVHD as well as immune recon-
stitution [9] in a cohort of patients undergoing allogeneic
PBSC transplantation. We also deﬁned a cut-off value
of gCD3/Tregs ratio (36) associated with the appearance
of aGVHD and CMV infection/disease, thus permitting us
to distinguish between low and high gCD3/Tregs ratio
allotransplantation patients at the time of the allograft
reinfusion, in terms of aGVHD and CMV infection/disease
risk during the post reinfusion time: LR predicts the
absence of aGVHD and less risk of CMV infection [9].
However, although the risk factors for survival after allo-
transplantation are well deﬁned [15,20], little is known
about the possible contribution of gCD3/Tregs ratio to
transplantation outcomes (ie, OS, NRM, DFS, and relapse
rates) in the human setting of allotransplantation. We
analyzed 74 allotransplantation patients: 65 from our earlier
study [9] and 9 new ones.
In a large recent study including only patients affected by
acute myeloid leukemia [21], the univariate 3-year estimated
probabilities of survival were around 39%, 37%, and 34% for
matched related donor, matched unrelated donor, and mis-
matched unrelated donor, respectively. Although our study
included 82% of acute myeloid leukemia patients, the
univariate 3-year probability of survival in the whole cohort
was generally better (53%). This may be because in our study
cohort, the hematopoietic cell transplantation-speciﬁc
comorbidity index [18] was predominantly lower than 3
(85% of patients), which yields an OS rate at 2 years of 56%
and 55% for a 0 and 1 to 2 hematopoietic cell transplantation-
speciﬁc comorbidity index score, respectively [22]. Never-
theless, at univariate (Figure 1A, B) and multivariate analysis
(Table 3), a low gCD3/Tregs ratio was the only factor corre-
lated with better OS and DFS rates. On this theoretical basis,
gCD3/Tregs ratio may be considered a useful tool for strati-
fying patients in terms of expected OS.
With regard to the 3-year NRM, our data (Figure 1C) are
similar to those reported in larger studies [20,21].Nevertheless, given there was no difference in terms of the
factors having an impact on NRM [15,20-23] between the LR
and HR groups (Table 2), the NRM disparity between the
two groups may conﬁrm that the gCD3/Tregs ratio is closely
linked with the onset of aGVHD and related deaths (Table 4).
In fact, it is well known that unless aGVHD patients beneﬁt
from steroid therapy, mortality is high, and standardized
treatment algorithms are lacking [24-27]. Thus, our data
conﬁrm the clinical importance of improving the outcome
of patients suffering from aGVHD, while maintaining the
GVL effect to avoid a potential rise in relapse and relapse-
related mortality. In fact, as already widely reported
[16,28,29], we too observed a higher cumulative incidence
of relapse in aGVHD patients (53%), although, surprisingly,
analyzing the relapse incidence between the LR and HR
groups in univariate (Figure 1D) and multivariate models
(Table 3), we did not ﬁnd any statistically signiﬁcant
difference.
Of note, gCD3/Tregs ratio does not show a similar impact
on relapse and NRM. In fact, gCD3/Tregs ratio has no impact
on relapse, while maintaining its contribution to NRM
(Table 3). gCD3/Tregs ratio seems to be a better tool to
predict patients’ risk of NRM without affecting the antileu-
kemic effects. In other words, LR allotransplantation patients
have less risk of NRM and a similar risk of relapse, as
compared with HR patients.
Actually, our data seem to conﬁrmwhat was described in
mice [2]: Tregs determine a suppressive effect on aGVHD
while preserving the GVL action. The LR might mean that
Tregs are able to act in suppressing or controlling aGVHD
[30], which still remains the leading cause of death after
allotransplantation. On the contrary, as already reported by
Wolf et al. [31] regarding graft Tregs content, in our study
cohort, the gCD3/Tregs ratio (regardless of LR and/or HR) did
not penalize patients in terms of relapse (Figure 1D, Table 3),
conﬁrming a differential action by Tregs on controlling
aGVHD and preventing relapse.
In conclusion, apart from an inhibition of aGVHD and
related advantage in terms of OS due to a reduction in the
NRM rate, the relapse rate does not seem to be affected by
gCD3/Tregs ratio. By either Treg depletion or adoptive
transfer of puriﬁed Treg cells, two studies [10,11] in mice
had already demonstrated that the relative ratio of donor-
type T reg cells and donor-type CD4þ/CD25þ T cells
(and not Tregs by themselves) would determine the
outcome of experimental aGVHD in vitro. Thus, the best
strategies targeting predominantly GVHD without
affecting GVL effect might include a graft balance compo-
sition in favor of Tregs, although there is recent evidence
[32] that high levels of graft Tregs might antagonize
successful engraftment. Therefore, future clinical
perspectives might be focused on both an optimal graft
composition (by means of graft engineering) and a gCD3/
Tregs ratioebased risk-stratiﬁed management (ie, differ-
ential aGVHD prophylaxis according to HR or LR status)
after allotransplantation.ACKNOWLEDGMENTS
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